Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    

 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 1,21 M
EBIT 2016 -15,0 M
Net income 2016 -11,9 M
Debt 2016 -
Yield 2016 -
Sales 2017 1,63 M
EBIT 2017 -26,0 M
Net income 2017 -22,7 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 14,1x
Capi. / Sales2017 10,4x
Capitalization 17,0 M
More Financials
Company
Cyclacel Pharmaceuticals, Inc. is a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates.It is engaged in discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
12/09 CYCLACEL PHARMACEUTICALS, INC. : Other Events (form 8-K)
12/01 Cyclacel’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Poten..
11/18 HERE’S WHY CYCLACEL PHARMACEUT : CYCC) Could Have A Rough December
11/16 CYCLACEL PHARMACEUTICALS : CYCC) Files An 8-K Results of Operations and Financia..
11/14 CYCLACEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
11/14 CYCLACEL PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, ..
11/14 Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results
11/07 Cyclacel Pharmaceuticals to Release Third Quarter 2016 Financial Results
09/21 STOCKS IN ACTION : Pfizer, Inc. Cyclacel Pharmaceuticals, Inc.
09/12 CYCLACEL PHARMACEUTICALS, INC. : Other Events (form 8-K)
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
06/07 Midday Gainers / Losers
06/06 Midday Gainers / Losers
06/06 Cyclacel's lead product candidates show encouraging results in early-stage st..
06/06 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/02 Some Ideas For The Next Celator
Advertisement
Chart CYCLACEL PHARMACEUTICALS I
Duration : Period :
Cyclacel Pharmaceuticals I Technical Analysis Chart | US23254L3069 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICA..7.17%17
AMGEN, INC.-11.63%106 716
GILEAD SCIENCES, INC.-28.16%95 779
CELGENE CORPORATION-5.25%87 962
REGENERON PHARMACEUTIC..-31.32%39 322
ACTELION LTD50.21%22 204
More Results